Clinical trial · Interventional
Lung Cancer Detection by Measuring Monocyte Activity
Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)
NCT02090166CI-TRIAL-00014049EDLCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose: To evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer. The study population will include a total of 950 participants, patients with lung cancer before any treatment, and healthy and COPD patients as a control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- lung cancer diagnosis
- description
- 4 arms will be included in the study: The groups sample size is as follows: Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects A blood test will be taken from each patient.
- interventionNames
- Other: Blood test
Primary outcomes (1)
- measure
- Positive and negative diagnosis (scored 0/1 dichotomously) of lung cancer
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria
1. Subject signed the informed consent.
2. Subject is between 18 to 90 years old.
3. Lung cancer diagnosis before any treatment
Exclusion Criteria
1. Lung cancer patients
2. Subject has been previously treated for any type of malignant or benign tumor (for example: colon or uterus polyps removal).
3. Subject has active infection or inflammation determined clinically at screening.
4. Subject is currently treated with concomitant medication related directly or can affect the immune system.
5. Subject lactating or undergoing fertility treatment.
6. Subject has impaired judgment.
7. Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.
8. Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation.
9. Known hypersensitivity and/or allergy
10. Drug or alcohol abuse (by history).
11. Subject is participating in any other clinical trial, drug or device study within 30 days prior sample collection
12. Relatives of the study investigators or employees of the study investigators are not allowed to participate in the study
\-References
Publications (0)
Data not yet available
No reference posted for this study.